{"id":11,"date":"2018-09-10T12:47:51","date_gmt":"2018-09-10T12:47:51","guid":{"rendered":"http:\/\/law-firm.bold-themes.com\/master-import\/?page_id=11"},"modified":"2021-10-01T14:28:27","modified_gmt":"2021-10-01T14:28:27","slug":"about","status":"publish","type":"page","link":"https:\/\/stuarttherapeutics.com\/about\/","title":{"rendered":"About"},"content":{"rendered":"

About Stuart Therapeutics<\/span><\/h4>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div><\/div>
<\/div>
ABOUT US<\/span><\/h6>\n

Stuart was founded in 2018 to champion a new approach to the treatment of chronic diseases.<\/span><\/h4>\n

Stuart\u2019s areas of interest are Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration.<\/p>\n<\/div>

<\/div>

Stuart Therapeutics (Stuart) is a clinical stage biopharmaceutical company focused on the development of a unique tissue reparative platform for eye diseases called PolyCol<\/em><\/strong>. PolyCol<\/em><\/strong><\/span> is a family of synthesized polypeptide sequences that are specifically designed to repair damaged extracellular matrix (ECM) helical collagen structures.\u00a0 These structures play an important role in healthy tissues and are damaged in chronic and acute\/traumatic disease processes and injuries.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div>
Stuart\u2019s areas of interest are Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration.<\/span><\/h5>\n<\/div>

\"AboutStuart Therapeutics (Stuart) is a clinical stage biopharmaceutical company focused on the development of a unique precision tissue reparative platform for eye diseases called PolyCol<\/strong><\/em>. PolyCol<\/strong><\/em> is a family of synthesized polypeptide sequences that are specifically designed to repair damaged extracellular matrix (ECM) collagen triple helix structures. These structures play an important role in healthy tissues and are damaged in chronic disease inflammatory processes. Stuart was founded in 2018, and the company was founded to champion a new approach to the treatment of chronic diseases.<\/p>\n<\/div>

<\/div>

\"StuartStuart Therapeutics was founded to bring a fresh point of view to the development of therapies for difficult to treat ophthalmic diseases. Our team brings a wide variety of proven clinical, pharmaceutical R&D, operational and partnering skills to support our venture. Our core inventor group identified the promise of\u00a0PolyCol<\/em><\/strong><\/span>\u00a0and has established broad patent coverage to provide the company with an array of options for partnering and internal development. The areas of medicine on which we are focused have affected all of the members of our team, either directly or indirectly. We have a passion for what we do, and a motivation to improve results for patients suffering from these conditions.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div>
Stuart Therapeutics\u2019 mission is the development of new and meaningful therapies that improve the lives of people that suffer from difficult to treat diseases.<\/span><\/span><\/h5><\/header>
<\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div><\/div>
<\/div>
PARTNERING<\/span><\/h6>\n<\/div>

Join Our Team<\/span><\/a><\/h4>\n<\/div>

Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol<\/strong><\/em> technology and associated patents through license. At Stuart Therapeutics, we are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications. We are interested in strategic partner relationships that will extend and accelerate our impact.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":4311,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false},"_links":{"self":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/11"}],"collection":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/comments?post=11"}],"version-history":[{"count":0,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/pages\/11\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media\/4311"}],"wp:attachment":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media?parent=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}